Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Pfizer Names Albert Bourla Group President; Vaccines, Oncology and Consumer Healthcare Business

Business Wire December 17, 2013

Heat Biologics, Inc. Appoints Dr. Anil K. Goyal as Vice President of Business Development

Marketwired December 17, 2013

Pfizer Declares First-Quarter 2014 Dividend

Business Wire December 16, 2013

Nodality, Inc. to Present at the Oppenheimer 24th Annual Healthcare Conference

Business Wire December 5, 2013

Pfizer Expands Clinical Trial Data Access Policy And Launches Data Access Portal

Business Wire December 4, 2013

Bullish Stocks Commentary: Pfizer Inc, Zynga Inc, OCZ Technology Group, EnteroMedics Inc

Accesswire December 4, 2013

Traders Buzz: Pfizer Inc, Chesapeake Energy Corporation, Alcatel Lucent SA, Advanced Micro Devices

Accesswire December 3, 2013

Pfizer Acquires Polocard, Poland's Leading Over-The-Counter Heart Attack Prevention Brand

Business Wire December 2, 2013

Just in Time for Peak Travel Season, Introducing New Robitussin® DM Max Liquid-Filled Capsules

Business Wire November 25, 2013

Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV

PR Newswire November 22, 2013

Pfizer's XALKORI® Granted Regular FDA Approval

Business Wire November 21, 2013

Pfizer and GSK to Initiate Study of Novel Combination Therapy in Patients with Melanoma

Business Wire November 21, 2013

Pfizer Announces FDA Approval of Supplemental Application to Expand XELJANZ® (tofacitinib citrate) Labeling to Include Additional Patient-Reported Outcomes Data for Adults with Moderately to Severely Active Rheumatoid Arthritis

Business Wire November 18, 2013

Pfizer Subsidiary, Wyeth LLC, To Redeem 5.500% Notes Due February 1, 2014

Business Wire November 14, 2013

Nodality, Inc. Announces Presentations at the 28th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Business Wire November 12, 2013

Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE® (sirolimus) In Renal Transplant Recipients

Business Wire November 8, 2013

The Global Revolution in Biotechnology and the Impact of Regenerative Medicine

Accesswire November 7, 2013

Former U.S. President Jimmy Carter And Pfizer Celebrate 15-Year Effort To Help End Blinding Trachoma As A Public Health Concern

Business Wire November 5, 2013

Pfizer Receives FDA Approval for a Prior Approval Supplement for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII

Business Wire November 4, 2013

ViiV Healthcare receives approval for Tivicay(TM) (dolutegravir) in Canada for the treatment of HIV

Canada NewsWire November 4, 2013